Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world. To advance the field, NIAID has resources available to assist investigators who wish to evaluate new technologies that are cost-effective, easy to use, and can monitor HIV disease, identify acute/early infection, and differentiate vaccine-induced immunity from HIV infection. Alternative test technologies may also be of interest, including HIV drug resistance testing, diagnosis of co-infecting pathogens, and Pharmacokinetics (PK) and Pharmacodynamics (PD) testing.
Through a specified contractor, NIAID can provide an independent evaluation of a product at no cost to the investigator. These services are offered to fill specific gaps in an investigator’s assay development plan to help advance the product towards large-scale clinical use and/or Food and Drug Administration approval. The evaluation may include testing in laboratories at domestic and international NIAID-sponsored clinical trial sites. The contractor will have ongoing communication with the investigator. When the evaluation is completed, the contractor will provide a detailed report to NIAID and the investigator.
- Investigator must be willing to provide the assay equipment, test kits, and reagents at no charge to NIAID and its contractors.
- Investigator must have a defined product and have preliminary data to support the continued development of that product. Please note that random screenings of new technologies without any accompanying preliminary data are poor candidates for these services.